NCT05697237 2023-01-25Carlizumab Plus Sovantinib in Second-line Treatment of Advanced or Metastatic CholangiocarcinomaFirst Affiliated Hospital Xi'an Jiaotong UniversityPhase NA Unknown60 enrolled